Trial · NCT03292016
Results by group81
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 81
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) | Subcutaneous APOKYN | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 250.2 | Geometric Coefficient of Variation 140.6 | L/h |
| Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) | Subcutaneous APO-go | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 253.7 | Geometric Coefficient of Variation 169.6 | L/h |
| Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) | APL-130277, Sublingual Thin Film | APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 1952.1 | Geometric Coefficient of Variation 44.3 | L/h |
| Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) | Subcutaneous APOKYN | APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 350.6 | Geometric Coefficient of Variation 4.0 | L/h |
| Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) | Subcutaneous APO-go | APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 299.2 | Geometric Coefficient of Variation 41.0 | L/h |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | APL-130277, Sublingual Thin Film | APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 4440.2 | Geometric Coefficient of Variation 72.0 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Subcutaneous APOKYN | APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 577.5 | Geometric Coefficient of Variation 44.3 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Subcutaneous APO-go | APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 469.3 | Geometric Coefficient of Variation 19.1 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | APL-130277, Sublingual Thin Film | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1733.4 | Geometric Coefficient of Variation 52.8 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Subcutaneous APOKYN | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 420.8 | Geometric Coefficient of Variation 193.7 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Subcutaneous APO-go | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 372.2 | Geometric Coefficient of Variation 231.1 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | APL-130277, Sublingual Thin Film | APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 3419.5 | Geometric Coefficient of Variation 67.4 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Subcutaneous APOKYN | APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 452.0 | Geometric Coefficient of Variation 14.7 | L |
| Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Subcutaneous APO-go | APL 30 mg, APOKYN 5 mg and APO-go 5 mg | 324.2 | Geometric Coefficient of Variation 73.7 | L |
| Terminal-phase Half-life (t½) | APL-130277, Sublingual Thin Film | APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 1.11 | Geometric Coefficient of Variation 15.6 | h |
| Terminal-phase Half-life (t½) | Subcutaneous APOKYN | APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 0.98 | Geometric Coefficient of Variation 9.9 | h |
| Terminal-phase Half-life (t½) | Subcutaneous APO-go | APL 20 mg, APOKYN 3 mg and APO-go 3 mg | 0.87 | Geometric Coefficient of Variation 12.6 | h |
| Terminal-phase Half-life (t½) | APL-130277, Sublingual Thin Film | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1.09 | Geometric Coefficient of Variation 34.3 | h |
| Terminal-phase Half-life (t½) | Subcutaneous APOKYN | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1.17 | Geometric Coefficient of Variation 20.6 | h |
| Terminal-phase Half-life (t½) | Subcutaneous APO-go | APL 25 mg, APOKYN 4 mg and APO-go 4 mg | 1.02 | Geometric Coefficient of Variation 19.7 | h |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03292016/results?page=3